CN113088463A - 一种具有益生特性的嗜酸乳杆菌及其应用 - Google Patents
一种具有益生特性的嗜酸乳杆菌及其应用 Download PDFInfo
- Publication number
- CN113088463A CN113088463A CN202110285880.1A CN202110285880A CN113088463A CN 113088463 A CN113088463 A CN 113088463A CN 202110285880 A CN202110285880 A CN 202110285880A CN 113088463 A CN113088463 A CN 113088463A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus acidophilus
- food
- lactobacillus
- acidophilus
- bacterial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 240000001046 Lactobacillus acidophilus Species 0.000 title claims abstract description 68
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 title claims abstract description 68
- 229940039695 lactobacillus acidophilus Drugs 0.000 title claims abstract description 68
- 239000006041 probiotic Substances 0.000 title abstract description 15
- 230000000529 probiotic effect Effects 0.000 title abstract description 15
- 235000018291 probiotics Nutrition 0.000 title abstract description 15
- 241000894006 Bacteria Species 0.000 claims abstract description 19
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 9
- 235000013305 food Nutrition 0.000 claims abstract description 9
- 239000004310 lactic acid Substances 0.000 claims abstract description 6
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 6
- 238000004321 preservation Methods 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 5
- 235000013402 health food Nutrition 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 235000021107 fermented food Nutrition 0.000 claims description 3
- 229940124622 immune-modulator drug Drugs 0.000 claims description 3
- 241000138865 Acidothrix acidophila Species 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 230000012010 growth Effects 0.000 abstract description 12
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 10
- 244000052616 bacterial pathogen Species 0.000 abstract description 7
- 241000588724 Escherichia coli Species 0.000 abstract description 6
- 241000607142 Salmonella Species 0.000 abstract description 5
- 241000191967 Staphylococcus aureus Species 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 5
- 206010059866 Drug resistance Diseases 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 244000005700 microbiome Species 0.000 abstract description 4
- 230000003115 biocidal effect Effects 0.000 abstract description 3
- 230000028993 immune response Effects 0.000 abstract description 2
- 230000007365 immunoregulation Effects 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 13
- 230000000968 intestinal effect Effects 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 10
- 210000004051 gastric juice Anatomy 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 7
- 241000186660 Lactobacillus Species 0.000 description 6
- 229940039696 lactobacillus Drugs 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 206010018910 Haemolysis Diseases 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000008588 hemolysis Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 235000020183 skimmed milk Nutrition 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000304886 Bacilli Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000002949 hemolytic effect Effects 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- 240000006024 Lactobacillus plantarum Species 0.000 description 2
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 2
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 2
- 241000193996 Streptococcus pyogenes Species 0.000 description 2
- 240000000851 Vaccinium corymbosum Species 0.000 description 2
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 2
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 235000021014 blueberries Nutrition 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 2
- 229940107187 fructooligosaccharide Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 244000005709 gut microbiome Species 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000003832 immune regulation Effects 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229940072205 lactobacillus plantarum Drugs 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000009629 microbiological culture Methods 0.000 description 2
- 239000012982 microporous membrane Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000006872 mrs medium Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 229940009289 bifidobacterium lactis Drugs 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- KLOIYEQEVSIOOO-UHFFFAOYSA-N carbocromen Chemical compound CC1=C(CCN(CC)CC)C(=O)OC2=CC(OCC(=O)OCC)=CC=C21 KLOIYEQEVSIOOO-UHFFFAOYSA-N 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007382 columbia agar Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000008975 immunomodulatory function Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229940068140 lactobacillus bifidus Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000011268 mixed slurry Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明公开了一种具有益生特性的嗜酸乳杆菌及其应用,属于微生物技术领域。本发明的嗜酸乳杆菌(Lactobacillus acidophilus)为保藏编号为CGMCC No.21802的嗜酸乳杆菌LA85,其属于人源乳酸菌,具有较高的抵抗胃肠道胁迫的能力,对条件致病菌大肠杆菌、沙门氏菌和金黄色葡萄球菌具有明显的抑制作用,对常见抗生素药物敏感,不具有耐药性,且该菌株具有生长速率快,生长周期短,活菌数量高,可有效调节机体免疫反应,能够用于制备免疫调节药物和用于食品领域。
Description
技术领域
本发明属于微生物技术领域,具体涉及一株具有益生特性的嗜酸乳杆菌及其应用。
背景技术
人类胃肠道中含有大量有益的细菌群落,它们对维持人体健康起着重要的作用。正常、稳定、有益的肠道微生物菌群具有多种生物学功能,如提高营养物质的消化和吸收,调节肠道微生物群的平衡,稳定肠道屏障的完整性,防御肠道病原菌粘附和侵袭,刺激宿主细胞和体液免疫反应。影响肠道菌群组成最常用的方法是饮食益生菌,多年来,许多种类的微生物被使用,它们主要由乳酸细菌和双歧杆菌组成,但也包括芽孢杆菌和真菌。传统的益生菌,如乳酸细菌和双歧杆菌,在预防疾病和促进人体健康方面均表现出积极的作用,具有较高的理论研究和产品应用价值。
益生菌是指活体微生物,当摄入足够数量时,给宿主带来健康益处。通过研究益生菌在模拟胃肠道中的存活情况、对病原菌生长的抑制能力、对药物的敏感性以及对胃肠道的黏附能力,进一步认识益生菌益生作用的机制及其在不同领域的应用价值。
乳酸菌是应用最广、时间最长、种类最多的一类益生菌,其中应用较为广泛的是乳酸杆菌,而嗜酸乳杆菌是乳酸杆菌家族中极为重视和研究开发的菌株之一,在乳制品工业中有广泛的历史应用,能够大量分泌乳酸、乙酸等酸性物质,能在酸性较强的胃液中生长繁殖,被称为胃部环境的“移动消毒车”,对维持胃肠道的生理功能有重要作用。嗜酸乳杆菌是乳酸菌的主要商业物种,因其风味和益生作用而被广泛添加到商业酸奶和乳制品配方,以及有益生作用的膳食补充剂中,是最常用的膳食乳酸菌品种之一,具有较高的应用价值。
发明内容
本发明的目的在于提供一株具有益生特性的嗜酸乳杆菌LA85及其应用。
本发明的目的通过下述技术方案实现:
一种具有益生特性的嗜酸乳杆菌LA85,其分类命名为嗜酸乳杆菌Lactobacillusacidophilus,该菌株于2021年02月01日保藏于中国微生物菌种保藏管理委员会普通微生物中心(CGMCC),地址为北京市朝阳区北辰西路1号院3号,保藏编号为CGMCC No.21802。
所述的嗜酸乳杆菌LA85具有以下特征:
(1)菌落形态:圆形、浅灰色、不透明,菌落较小,边缘不规则,表面凸起不湿润;
(2)菌体形态:革兰氏阳性杆菌,有短杆、长杆形态,两端钝圆,不产芽孢;
(3)生长特点:培养基最适pH为6.0,最适温度为37℃,生长快,4h进入对数生长期,10h进入稳定期。
所述的嗜酸乳杆菌LA85具有以下益生特性:
(1)在pH2.5的人工胃液中处理3h,其存活率为99.07%;
(2)在pH8.0的人工肠液中处理3h,其存活率为98.93%;
(3)对常见的条件致病菌大肠杆菌、沙门氏菌和金黄色葡萄球菌的生长有很强的抑制作用;
(4)对常见抗生素药物表现出不同程度的敏感性,不具备耐药性。
本发明所述的嗜酸乳杆菌LA85可以调节小鼠体内免疫相关的细胞因子水平,其具有免疫调节功能,可用于制备免疫调节药物。
一种免疫调节药物,包含所述的嗜酸乳杆菌LA85。
所述的嗜酸乳杆菌LA85还可用于食品领域,如保健食品、含活性乳酸菌的食品或发酵食品等。所述的保健食品包括但不限于发酵食品或微生态制剂。
一种食品,包含所述的嗜酸乳杆菌LA85。
本发明的有益效果在于:本发明所提供的嗜酸乳杆菌LA85属于人源乳酸菌,其具有较高的抵抗胃肠道胁迫的能力,对条件致病菌大肠杆菌、沙门氏菌和金黄色葡萄球菌具有明显的抑制作用,对常见抗生素药物敏感,不具有耐药性,且该菌株具有生长速率快,生长周期短,活菌数量高,可有效调节机体免疫反应。
附图说明
图1为嗜酸乳杆菌LA85在MRS平板培养基上的菌落形态图。
图2为嗜酸乳杆菌LA85经革兰氏染色后的菌体形态图。
图3为嗜酸乳杆菌LA85在MRS培养基中的生长曲线及pH曲线图。
具体实施方式
下面结合实施例对本发明作进一步详细的描述,但本发明的实施方式不限于此。实施例中未作详细描述的内容属于本领域专业技术人员公知的现有技术。
实施例1嗜酸乳杆菌LA85的分离筛选与鉴定
(1)菌株的分离筛选
菌株分离自健康人体粪便,具体分离筛选方法如下:
取健康人体粪便样品1g至9mL生理盐水中,充分振荡分散样品,取100μL样品梯度稀释,选取10-1、10-2、10-3菌液各100μL均匀涂布于MRS平板,置于厌氧条件下,37℃培养36~48h后,挑选疑似菌落,对其镜检观察并进行初步筛选和纯化培养。
MRS培养基配方(g/L):蛋白胨10、牛肉浸粉5、酵母粉5、葡萄糖20、无水乙酸钠5、柠檬酸氢二铵2、吐温80 1、K2HPO4 2、MgSO4 0.2、MnSO4 0.05,pH6.5,121℃高压灭菌20min,固体MRS培养基中加入1.5%的琼脂粉。
(2)菌株的形态学和16S rDNA鉴定
形态学鉴定包括菌株在平板培养基上的菌落形态以及革兰氏染色后显微镜下的菌体形态。
本发明的嗜酸乳杆菌LA85的菌落和菌体形态见图1和2。菌落呈圆形、浅灰色、不透明,边缘整齐,直径约1~2mm,表面干燥凸起。菌体形态为革兰氏阳性杆菌,单个或成对排列。
对筛选的目的菌株液体扩培,收集菌体,提取基因组DNA,采用通用引物27F:AGAGTTTGATCCTGGCTCAG和1492R:GGTTACCTTGTTACGACTT扩增其16S rDNA片段,用琼脂糖凝胶电泳检测PCR扩增产物。将获得的目的片段进行测序分析,测序结果在NCBI数据库中进行比对分析,鉴定所得菌株为嗜酸乳杆菌,其分类命名为嗜酸乳杆菌Lactobacillusacidophilus,该菌株已于2021年02月01日保藏于中国微生物菌种保藏管理委员会普通微生物中心(CGMCC),地址:北京市朝阳区北辰西路1号院3号,中国科学院微生物研究所,邮编100101,保藏编号为CGMCC No.21802,菌株编号为LA85。
实施例2嗜酸乳杆菌LA85生长曲线和pH曲线
将嗜酸乳杆菌LA85活化后种子液以2%(V/V)接种量转接至10mL的新鲜MRS液体培养基中,37℃厌氧培养24h,定时取样,测定培养液的OD600和pH,每个样品3组重复,以培养时间为横坐标,OD600或pH值为纵坐标,绘制菌株生长曲线和pH曲线(见图3)。嗜酸乳杆菌LA85在4h进入对数生长期,10h进入稳定期,发酵周期短。pH曲线在0-10h缓慢下降,10h后pH维持在4.0左右。
实施例3嗜酸乳杆菌LA85对人工胃肠液耐受性
人工胃液配方:配制0.85%生理盐水,用稀盐酸调节pH至2.5,然后加入0.3%胃蛋白酶,充分溶解后用微孔滤膜过滤除菌备用。
人工肠液配方:配制0.85%生理盐水,用氢氧化钠调节pH至8.0,然后加入0.1%胰蛋白酶,充分溶解后用微孔滤膜过滤除菌备用。
活化实验菌株至稳定期,以2%(V/V)比例分别转入上述配制的人工胃液和人工肠液中,每个处理3组重复,测定处理液中活菌数,然后置于37℃孵育3h后,再次测定处理液中活菌数,采用公式存活率(%)=(logN3/logN0)×100%计算菌株存活率,其中N3为人工胃液/肠液处理3h后的活菌数,N0为处理0h的活菌数。嗜酸乳杆菌LA85在人工胃液和人工肠液中的耐受结果见表1。由表1可知,该菌株在人工胃液、肠液中处理3h后保持非常高的存活率,表明该菌株具有良好的耐受胃肠液的能力。
表1嗜酸乳杆菌LA85对人工胃液、人工肠液耐受存活率
实施例4嗜酸乳杆菌LA85对病原菌的抑制能力
指示菌悬液的制备:将大肠杆菌、沙门氏菌和金黄色葡萄球菌分别在平板培养基上活化,37℃培养24h,挑取菌苔至生理盐水制备菌悬液,调整菌液浓度至108-1010CFU/mL。
嗜酸乳杆菌LA85发酵液制备:将嗜酸乳杆菌LA85按1%(V/V)接种至MRS液体培养基中,37℃厌氧培养12h。
抑菌实验:将含有1.5%琼脂的MRS肉汤培养基冷却至55℃左右,与指示菌悬液按一定比例混匀,使指示菌的活菌数在106CFU/mL或108CFU/mL数量级,然后迅速倾注于预先放置牛津杯的平板中,待培养基冷却凝固后,取出牛津杯,于每孔注入200μL嗜酸乳杆菌LA85发酵液(活菌数为108CFU/mL数量级),37℃过夜培养后,测量抑菌圈直径。结果如表2所示。
表2嗜酸乳杆菌LA85发酵液对病原菌的抑制作用
由上表可得,当指示菌浓度106CFU/mL时,嗜酸乳杆菌LA85对金黄色葡萄球菌、大肠杆菌和沙门氏菌的生长有非常强的抑制作用,尤其对大肠杆菌的抑制作用最强,抑菌圈直径达到44mm。当把指示菌浓度调整至108CFU/mL时,嗜酸乳杆菌LA85对三种病原菌仍表现出了较强的抑制作用。
实施例5嗜酸乳杆菌LA85细胞表面疏水性测定
将嗜酸乳杆菌LA85在MRS液体培养基种过夜培养,取20mL菌液离心、去上清,收集菌体,用PBS缓冲液清洗细胞2次后,用PBS重悬,充分振荡打散细胞,调整菌体浓度为OD600约1.0,取15mL菌液至试管,加入5mL二甲苯,以不加二甲苯的菌液为对照,然后充分振荡,静置20min后,出现分层,取下层水相,测定OD600,计算菌株疏水力(%)=(1-At/A0)×100%,其中At为菌液与二甲苯混匀后水相OD600值,A0为菌液初始OD600值。
结果显示,嗜酸乳杆菌LA85菌体经二甲苯处理前后的OD600值分别为0.649和0.059,菌株对二甲苯疏水力为90.9%。表明菌株在肠黏膜表面具很强的黏附性,有助于菌株在肠道内更好的发挥益生功效。
实施例6嗜酸乳杆菌LA85的安全性评价
(1)对常见药物敏感性评价
将嗜酸乳杆菌LA85在MRS固体平板上划线活化后,挑取菌苔至生理盐水中制备菌悬液,调整菌悬液浓度为108CFU/mL,取100μL菌悬液,用无菌棉签均匀涂布于MRS固体平板上,将抗生素药敏试纸片有序置于平板表面,置于厌氧条件下,37℃培养24-36h后,用游标卡尺测量抑菌圈直径。
根据美国临床和实验标准协会CLSI的评价标准,得到菌株对17种常用抗生素敏感性结果,见表3,嗜酸乳杆菌LA85对这些药物敏感,说明该菌株安全,可潜在的用于生物制品或膳食补充剂。
表3嗜酸乳杆菌LA85对抗生素的敏感性
注:S-敏感;I-中度耐药。
(2)溶血性实验
以化脓性链球菌作为对照,对菌株进行溶血实验。化脓性链球菌接种于哥伦比亚琼脂平板培养后菌落周围出现透明的溶血圈,是乙型溶血(β溶血);而嗜酸乳杆菌LA85接种于该培养基后,菌落周围未出现溶血圈,因此判断该菌株没有溶血性,不会产生溶血性危害。
实施例7嗜酸乳杆菌LA85的免疫调节功能
实验动物:SPF级BLAB/c,6-8周幼龄雄性小鼠。
动物饲喂:所有实验小鼠均饲养于塑料笼中,标准膳食,自由饮水。环境温度:23±1℃,湿度55±10%。
动物分组及益生菌干预:将小鼠随机分为2组,分别为对照组和嗜酸乳杆菌LA85干预组,每组12只小鼠。对照组:每只小鼠每天灌胃100μL 10%(w/v)脱脂奶粉;嗜酸乳杆菌LA85干预组:每只小鼠每天灌胃100μL含108CFU嗜酸乳杆菌LA85的10%(w/v)脱脂奶粉,持续喂养14天。
免疫组织样本制备:在14天饲养实验结束后,分别处死小鼠,取出小肠,解剖成段,固定在95%酒精中,然后将组织包埋在石蜡块中进行免疫荧光检测。
免疫荧光检测分泌IgA细胞数量:用直接免疫荧光法测定小鼠小肠组织切片中IgA分泌细胞数量,组织学切片在二甲苯中浸泡,再在乙醇中水化,在室温用1%的牛血清蛋白蛋白封闭液孵育30min,然后在37℃条件下将组织切片与异硫氰酸荧光素(FITC)标记的抗IgA特异性抗体在0.01M PBS缓冲液中共同孵育30min,孵育结束后用PBS溶液洗涤3次,用荧光显微镜观察10个视野中阳性荧光细胞数量,实验结果见表4。
表4嗜酸乳杆菌LA85对小鼠小肠产生IgA细胞的影响
注:*表示与对照组比较,差异有统计学意义(P<0.001)。
血清细胞因子检测:处死小鼠后,收集血液,并在4℃过夜凝固,然后用2000rpm,10min离心从血液中提取血清,用ELISA试剂盒分别测定不同处理组小鼠血清中IL-12和IFN-γ的含量,结果见表5。
表5小鼠血清中IL-12和IFN-γ细胞因子检测
注:*表示与对照组比较,差异有统计学意义(P<0.01)。
结果显示,小鼠在饲喂嗜酸乳杆菌LA85 14天后,小肠内产IgA细胞的数量增加,同时提高了小鼠血清中IL-12水平,降低了IFN-γ的水平。胃肠道中IgA在保护粘液表面免受致病性菌感染和致癌方面起着积极的作用;IL-12是在细菌及其代谢产物刺激下,巨噬细胞释放的一种细胞因子,主要作用是增强细胞免疫能力,在抗肿瘤免疫中发挥正向调节作用;IFN-γ,一种Th1型细胞因子,在宿主中有多个功能,主要在细胞免疫反应中释放,参与抗肿瘤和抗感染反应。综上所述,用嗜酸乳杆菌LA85饲喂小鼠后,可以调节小鼠体内免疫相关的细胞因子水平,对小鼠起免疫调节作用。
实施例8含嗜酸乳杆菌LA85益生菌固体饮料的制备
含嗜酸乳杆菌的益生菌固体饮料由以下原料制备而成:菊粉(43%)、低聚果糖(20%)、脱脂乳粉、赤藓糖醇、麦芽糊精、蓝莓水果粉、嗜酸乳杆菌、乳双岐杆菌、植物乳杆菌、鼠李糖乳杆菌。制备此固体饮料的具体方法为:称取麦芽糊精按1:4~1:6重量比投入70℃温水中,充分搅拌至完全溶解后过80目筛,得到浆液待用;称取菊粉、低聚果糖、脱脂乳粉、赤藓糖醇、蓝莓水果粉,投入沸腾制粒机中,设置温度65℃,引风频率28Hz,混料20min至均匀,得到混合物料;更改设置沸腾制粒机温度至55℃,引风频率28Hz,将混合浆液在压力0.1MPa,流速80r/min条件下喷入沸腾制粒机中的混合物料中,喷浆时间50min至物料出现颗粒度均匀的状态,得到造粒体;更改设置沸腾制粒机温度65℃,引风频率25Hz,将造粒体干燥20min后停止加热,待料温降至50℃以下后收料;将所收料与嗜酸乳杆菌、乳双岐杆菌、植物乳杆菌、鼠李糖乳杆菌均匀混合后分装。并对3个批次固体饮料的活菌量进行活菌检测,结果表明本发明的益生菌固体饮料,其益生菌活菌量大于1×1010CFU/g。
上述实施例为本发明较佳的实施方式,但本发明的实施方式并不受上述实施例的限制,其他的任何未背离本发明的精神实质与原理下所作的改变、修饰、替代、组合、简化,均应为等效的置换方式,都包含在本发明的保护范围之内。
Claims (7)
1.一种嗜酸乳杆菌(Lactobacillus acidophilus),其特征在于:所述的嗜酸乳杆菌为保藏编号为CGMCC No.21802的嗜酸乳杆菌 LA85。
2.权利要求1所述的嗜酸乳杆菌在食品领域中的应用。
3.根据权利要求2所述的应用,其特征在于:所述的食品领域包括保健食品、含活性乳酸菌的食品或发酵食品。
4.根据权利要求2所述的应用,其特征在于:所述的保健食品包括微生态制剂。
5.一种食品,其特征在于:所述的食品包含权利要求1所述的嗜酸乳杆菌。
6.权利要求1所述的嗜酸乳杆菌在制备免疫调节药物中的应用。
7.一种免疫调节药物,其特征在于:所述的免疫调节药物包含权利要求1所述的嗜酸乳杆菌。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110285880.1A CN113088463B (zh) | 2021-03-17 | 2021-03-17 | 一种具有益生特性的嗜酸乳杆菌及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110285880.1A CN113088463B (zh) | 2021-03-17 | 2021-03-17 | 一种具有益生特性的嗜酸乳杆菌及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113088463A true CN113088463A (zh) | 2021-07-09 |
CN113088463B CN113088463B (zh) | 2022-07-15 |
Family
ID=76668308
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110285880.1A Active CN113088463B (zh) | 2021-03-17 | 2021-03-17 | 一种具有益生特性的嗜酸乳杆菌及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113088463B (zh) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113755370A (zh) * | 2021-08-23 | 2021-12-07 | 微康益生菌(苏州)股份有限公司 | 嗜酸乳杆菌la85在制备降血脂药物或保健食品上的应用 |
CN114395514A (zh) * | 2022-02-28 | 2022-04-26 | 鲁东大学 | 一株嗜酸乳杆菌、菌剂及其应用 |
CN114686407A (zh) * | 2022-05-13 | 2022-07-01 | 微康益生菌(苏州)股份有限公司 | 一种提高可培养细胞含量的嗜酸乳杆菌菌粉的制备方法 |
CN115119940A (zh) * | 2021-12-23 | 2022-09-30 | 微康益生菌(苏州)股份有限公司 | 嗜酸乳杆菌LA85和乳双歧杆菌BLa80在抑制幽门螺旋杆菌上的应用 |
CN115428834A (zh) * | 2022-10-18 | 2022-12-06 | 微康益生菌(苏州)股份有限公司 | 一种具有舒压助眠功效的酸奶及其制备方法和应用 |
CN116019842A (zh) * | 2023-02-20 | 2023-04-28 | 微康益生菌(苏州)股份有限公司 | 嗜酸乳杆菌la85的抑菌新用途及其在制备缓解eiec腹泻的药物方面的用途 |
CN116515684A (zh) * | 2023-03-29 | 2023-08-01 | 微康益生菌(苏州)股份有限公司 | 一种改善高磷血症的益生菌剂及其应用 |
CN118620805A (zh) * | 2024-08-14 | 2024-09-10 | 微康益生菌(苏州)股份有限公司 | 一种防治肠道炎症的益生菌组合物及其应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105400726A (zh) * | 2015-12-21 | 2016-03-16 | 南昌大学 | 一株抗胃肠道胁迫的人源性嗜酸乳杆菌及其应用 |
CN105420150A (zh) * | 2015-12-08 | 2016-03-23 | 东北农业大学 | 一种嗜酸乳杆菌及其应用 |
CN111387506A (zh) * | 2020-03-24 | 2020-07-10 | 山东凤凰生物有限公司 | 一种嗜酸乳杆菌的用途及含所述嗜酸乳杆菌的组合物 |
-
2021
- 2021-03-17 CN CN202110285880.1A patent/CN113088463B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105420150A (zh) * | 2015-12-08 | 2016-03-23 | 东北农业大学 | 一种嗜酸乳杆菌及其应用 |
CN105400726A (zh) * | 2015-12-21 | 2016-03-16 | 南昌大学 | 一株抗胃肠道胁迫的人源性嗜酸乳杆菌及其应用 |
CN111387506A (zh) * | 2020-03-24 | 2020-07-10 | 山东凤凰生物有限公司 | 一种嗜酸乳杆菌的用途及含所述嗜酸乳杆菌的组合物 |
Non-Patent Citations (4)
Title |
---|
CHUNG-YI WANG等: "Probiotic properties of Lactobacillus strains isolated from the feces of breast-fed infants and Taiwanese pickled cabbage", 《ANAEROBE》 * |
MINYU SONG等: "Characterization of Selected Lactobacillus Strains for Use as Probiotics", 《KOREAN J. FOOD SCI. AN.》 * |
洪梅等: "一株嗜酸乳杆菌的抑菌效果及相关特性分析", 《黑龙江畜牧兽医》 * |
蔡熙姮 等: "蓝狐源嗜酸乳杆菌ZJBF003株的分离鉴定及其体外益生潜能的评价", 《中国兽医科学》 * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113755370A (zh) * | 2021-08-23 | 2021-12-07 | 微康益生菌(苏州)股份有限公司 | 嗜酸乳杆菌la85在制备降血脂药物或保健食品上的应用 |
CN113755370B (zh) * | 2021-08-23 | 2023-11-14 | 微康益生菌(苏州)股份有限公司 | 嗜酸乳杆菌la85在制备降血脂药物或保健食品上的应用 |
CN115119940A (zh) * | 2021-12-23 | 2022-09-30 | 微康益生菌(苏州)股份有限公司 | 嗜酸乳杆菌LA85和乳双歧杆菌BLa80在抑制幽门螺旋杆菌上的应用 |
CN115119940B (zh) * | 2021-12-23 | 2024-10-01 | 微康益生菌(苏州)股份有限公司 | 嗜酸乳杆菌LA85和乳双歧杆菌BLa80在抑制幽门螺旋杆菌上的应用 |
CN114395514B (zh) * | 2022-02-28 | 2023-09-01 | 鲁东大学 | 一株嗜酸乳杆菌、菌剂及其应用 |
CN114395514A (zh) * | 2022-02-28 | 2022-04-26 | 鲁东大学 | 一株嗜酸乳杆菌、菌剂及其应用 |
CN114686407A (zh) * | 2022-05-13 | 2022-07-01 | 微康益生菌(苏州)股份有限公司 | 一种提高可培养细胞含量的嗜酸乳杆菌菌粉的制备方法 |
CN115428834A (zh) * | 2022-10-18 | 2022-12-06 | 微康益生菌(苏州)股份有限公司 | 一种具有舒压助眠功效的酸奶及其制备方法和应用 |
CN115428834B (zh) * | 2022-10-18 | 2024-03-12 | 微康益生菌(苏州)股份有限公司 | 一种具有舒压助眠功效的酸奶及其制备方法和应用 |
CN116019842A (zh) * | 2023-02-20 | 2023-04-28 | 微康益生菌(苏州)股份有限公司 | 嗜酸乳杆菌la85的抑菌新用途及其在制备缓解eiec腹泻的药物方面的用途 |
CN116019842B (zh) * | 2023-02-20 | 2023-08-25 | 微康益生菌(苏州)股份有限公司 | 嗜酸乳杆菌la85的抑菌新用途及其在制备缓解eiec腹泻的药物方面的用途 |
CN116515684A (zh) * | 2023-03-29 | 2023-08-01 | 微康益生菌(苏州)股份有限公司 | 一种改善高磷血症的益生菌剂及其应用 |
CN116515684B (zh) * | 2023-03-29 | 2024-03-01 | 微康益生菌(苏州)股份有限公司 | 一种改善高磷血症的益生菌剂及其应用 |
CN118620805A (zh) * | 2024-08-14 | 2024-09-10 | 微康益生菌(苏州)股份有限公司 | 一种防治肠道炎症的益生菌组合物及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN113088463B (zh) | 2022-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113088463B (zh) | 一种具有益生特性的嗜酸乳杆菌及其应用 | |
CN111484957B (zh) | 动物双歧杆菌乳亚种i797、其分离纯化方法及应用 | |
CN112852679B (zh) | 一株益生凝结芽孢杆菌及其应用 | |
JP5186077B2 (ja) | ラクトバシラス−カゼイke01株から得られたプロバイオティック化合物 | |
CN101260377B (zh) | 一种动物双歧杆菌及其用途 | |
CN112812999B (zh) | 一株对阴沟肠杆菌具有抑制作用的植物乳杆菌slb01及其衍生产品和应用 | |
CN113832058A (zh) | 乳双歧杆菌BLa80在制备降血脂和调节肠道菌群的药物或食品中的应用 | |
CN110964655A (zh) | 一种可调节胃肠道菌群的乳双歧杆菌bl-99及其应用 | |
CN110964658B (zh) | 一种具有免疫调节功能的副干酪乳杆菌et-22 | |
CN110157645B (zh) | 一种唾液乳杆菌y4及其应用 | |
CN109055268A (zh) | 一种复合微生态制剂及其在蜜蜂养殖过程中的应用 | |
CN111849810A (zh) | 拮抗幽门螺旋杆菌的乳酸菌zjuids03及其应用 | |
CN118374422B (zh) | 一株罗伊氏粘液乳杆菌lr1218及其应用 | |
CN104522648A (zh) | 一种四联益生菌制剂及应用 | |
CN113337440B (zh) | 一株唾液乳杆菌mg-587及其应用 | |
CN111543640A (zh) | 一种具有改善小儿腹泻和消化不良的动物双歧杆菌乳亚种i797的应用 | |
CN113088468B (zh) | 干酪乳杆菌Ma.GLRGJ 1及其应用 | |
CN116790432A (zh) | 能够改善肠道健康的母乳源植物乳杆菌、微生物菌剂及其应用 | |
CN116790431A (zh) | 能够缓解便秘与腹泻的婴儿源动物双歧杆菌乳亚种、微生物菌剂及其应用 | |
CN117327607A (zh) | 动物双歧杆菌菌株冻干制剂及其制备方法和用途 | |
CN105733978A (zh) | 一株屎肠球菌wefa23 | |
CN116200305A (zh) | 一株具有抗炎特性的耐久肠球菌菌株、培养方法及应用 | |
CN113430153B (zh) | 降血压的罗伊氏乳杆菌zjuids09及其应用 | |
KR101098946B1 (ko) | 신규한 락토바실러스 살리바리우스 균주 및 이를 함유하는 사료첨가제 조성물 | |
CN112538441A (zh) | 缓解etec所致腹泻的罗伊氏乳杆菌ccfm1144及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |